title: Effect of serotype on focus and mortality of invasive pneumococcal disease: coverage of different vaccines and insight into non-vaccine serotypes.
abstract: BACKGROUND
  Differences in pathogenicity between pneumococcal serotypes are important when assessing the potential benefit of different valency vaccines. We investigated the effect of serotype on clinical presentation, outcome, and quality of life lost from invasive pneumococcal disease (IPD) in the context of the 7, 10, and 13 valent pneumococcal conjugate vaccines (PCV7, PCV10, PCV13).
  
  
  METHODS
  Serotyped IPD cases in England were linked to the national dataset of hospital admissions for April 2002 to March 2011. Based on patients' diagnostic codes and vital status at the end of the admission, disease focus (meningitis, empyema, sepsis, or respiratory disease) and case fatality rates by serotype and age group (5, 5-64, and 65 years and over) were obtained. Using these data the quality adjusted life years (QALY) lost from the IPD remaining when use of PCV7 stopped in 2010 was estimated for the serotypes covered by higher valency vaccines.
  
  
  RESULTS
  The linked dataset contained 23,688 cases with information on diagnosis, mortality, and serotype. There were significant differences between serotypes in the propensity to cause meningitis, death, and QALY loss in each of the investigated age groups. As a result, vaccines' coverage of disease burden differed by endpoint. For example, in children under 5 years in 2009/10, PCV10 covered 39% of meningitis, 19% of deaths and 28% of the QALY loss of attributable to IPD, whereas the respective percentages for PCV13 were 65%, 67%, and 66%. The highest QALY loss per serotype in this age group was for 6A. Non-PCV serotypes causing the highest QALY loss were 22F and 33F in <5 year olds and 31 in older individuals.
  
  
  CONCLUSIONS
  Marked differences exist between serotypes in clinical presentation and outcome, and these should be considered when evaluating the potential impact of higher valency vaccines on overall disease burden and associated QALY loss.
authors: Immunisation, Hepatitis and Blood Safety Department, Health Protection Agency, London, United Kingdom. albertjan.vanhoek@hpa.org.uk
authors: Albert Jan
authors: AJ
authors: van Hoek
authors: Nick
authors: N
authors: Andrews
authors: Pauline A
authors: PA
authors: Waight
authors: Robert
authors: R
authors: George
authors: Elizabeth
authors: E
authors: Miller
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D001428:Bacterial Vaccines; D002648:Child; D002675:Child, Preschool; D006801:Humans; D008875:Middle Aged; D011008:Pneumococcal Infections / Q000382:microbiology* / Q000401:mortality* / Q000517:prevention & control; D011788:Quality of Life; D019057:Quality-Adjusted Life Years; D012703:Serotyping; D013045:Species Specificity; D013296:Streptococcus pneumoniae / Q000145:classification* / Q000276:immunology*; D018074:Vaccines, Conjugate; D055815:Young Adult
chemical_list: D001428:Bacterial Vaccines; D018074:Vaccines, Conjugate